

ASX Announcement and Media Release

Wednesday, April 1, 2009

SciGen Limited

SCI GEN SHARES TEMPORARILY SUSPENDED FROM OFFICIAL QUOTATION

SciGen Limited ("SciGen") announced today that it has not submitted its Annual Financial Statements for the 12 months ended 31 December 2008 to ASX on the due date of 31st March 2009. Accordingly its shares have been suspended.

When issuing the Preliminary Results for the 12 months ended 31 December 2008 reference was made to SciGen's reliance on Bioton S.A., to provide financial support to enable it to operate as a going concern. BIOTON S.A. has been negotiating to refinance its borrowings and is currently in the midst of raising capital in the Polish market. The completion of this exercise is awaiting the approval of Bioton shareholder's at an Extraordinary General Meeting to be held on the 6th of April 2009. Said approval is not expected to be withheld.

The Capital raising will be completed by the end of April 2009 and a successful outcome is anticipated at which time BIOTON S.A. which has confirmed that it will have the ability and willingness to continue to support the investments and cash requirements of SciGen Ltd will be reaffirmed and the Annual Financial Statements released to ASX if not sooner.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988 by its founder, Chairman & CEO Mr. Saul Mashaal. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in the USA, Canada, Australia, S.Korea, Vietnam, Hong Kong and Philippines, distribution channels in Taiwan, China, Malaysia, India, Pakistan, Thailand and Indonesia, manufacturing facilities in Israel, India and China and a contract manufacturer in Poland, Bioton S.A.

=====ENDS=====

Media enquiries

Saul Mashaal

Founder, Chairman & CEO

Telephone:

Australia : +61 2 9234 1700

Singapore: +65 96305691

USA : +1 612 3097747

Web: www.scigen.com.au